7.22
price down icon0.41%   -0.03
after-market Dopo l'orario di chiusura: 7.16 -0.06 -0.83%
loading
Precedente Chiudi:
$7.25
Aprire:
$7.255
Volume 24 ore:
3.29M
Relative Volume:
1.10
Capitalizzazione di mercato:
$1.52B
Reddito:
$557.51M
Utile/perdita netta:
$-35.71M
Rapporto P/E:
-40.11
EPS:
-0.18
Flusso di cassa netto:
$15.50M
1 W Prestazione:
+0.98%
1M Prestazione:
-9.86%
6M Prestazione:
+12.64%
1 anno Prestazione:
+1.40%
Intervallo 1D:
Value
$7.08
$7.32
Intervallo di 1 settimana:
Value
$6.935
$7.335
Portata 52W:
Value
$6.015
$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
Nome
Biocryst Pharmaceuticals Inc
Name
Telefono
919-859-1302
Name
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
Dipendente
580
Name
Cinguettio
@biocrystpharma
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
7.22 1.52B 557.51M -35.71M 15.50M -0.18
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
141.11 63.55B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.71 44.47B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.00 40.17B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.03 22.99B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
440.00 20.14B 3.08B 1.24B 1.07B 25.61

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-01 Downgrade Evercore ISI Outperform → In-line
2025-04-29 Iniziato Cantor Fitzgerald Overweight
2025-02-25 Iniziato Wedbush Outperform
2023-11-20 Ripresa JP Morgan Overweight
2023-09-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-08-04 Aggiornamento Jefferies Hold → Buy
2023-07-13 Aggiornamento BofA Securities Neutral → Buy
2023-02-22 Aggiornamento Needham Hold → Buy
2022-11-02 Aggiornamento Evercore ISI In-line → Outperform
2022-08-05 Downgrade Evercore ISI Outperform → In-line
2022-08-05 Downgrade Oppenheimer Outperform → Perform
2022-04-18 Downgrade Barclays Overweight → Equal Weight
2022-04-11 Downgrade BofA Securities Buy → Neutral
2021-12-10 Iniziato Oppenheimer Outperform
2021-08-06 Downgrade Jefferies Buy → Hold
2021-08-03 Iniziato Cantor Fitzgerald Overweight
2021-03-01 Iniziato Cowen Outperform
2020-09-29 Ripresa JP Morgan Overweight
2020-06-17 Iniziato BTIG Research Neutral
2020-05-05 Aggiornamento Barclays Equal Weight → Overweight
2019-11-15 Aggiornamento BofA/Merrill Neutral → Buy
2019-05-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
2018-11-16 Ripresa Piper Jaffray Overweight
2018-08-08 Ripresa JP Morgan Overweight
2018-07-17 Aggiornamento BofA/Merrill Underperform → Neutral
2018-06-22 Iniziato Seaport Global Securities Neutral
2018-01-02 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2017-12-20 Iniziato Barclays Equal Weight
2017-09-15 Iniziato RBC Capital Mkts Sector Perform
2017-09-06 Aggiornamento JP Morgan Neutral → Overweight
2017-09-06 Aggiornamento Jefferies Hold → Buy
2017-02-16 Iniziato Ladenburg Thalmann Buy
2016-08-12 Aggiornamento Piper Jaffray Neutral → Overweight
2016-08-04 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Reiterato FBR Capital Outperform
2016-02-09 Downgrade JP Morgan Overweight → Neutral
2016-02-09 Downgrade Needham Buy → Hold
Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

pulisher
10:49 AM

How high can BioCryst Pharmaceuticals Inc. stock goAnalyst Downgrade & Fast Entry High Yield Stock Tips - newser.com

10:49 AM
pulisher
06:52 AM

Multi factor analysis applied to BioCryst Pharmaceuticals Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com

06:52 AM
pulisher
03:17 AM

Has BioCryst Pharmaceuticals Inc. formed a bullish divergenceTrade Analysis Report & Risk Managed Investment Signals - newser.com

03:17 AM
pulisher
02:43 AM

How BioCryst Pharmaceuticals Inc. stock reacts to oil pricesAnalyst Upgrade & Proven Capital Preservation Tips - newser.com

02:43 AM
pulisher
Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX) - The Globe and Mail

Oct 09, 2025
pulisher
Oct 09, 2025

Is BioCryst Pharmaceuticals Inc. stock poised for growthJuly 2025 Patterns & Stock Portfolio Risk Management - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

BioCryst Pharma Nears Defining FDA Moment For Pediatric HAE Therapy - RTTNews

Oct 09, 2025
pulisher
Oct 09, 2025

Quantitative breakdown of BioCryst Pharmaceuticals Inc. recent moveDip Buying & Low Drawdown Trading Techniques - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Zacks Research - MarketBeat

Oct 08, 2025
pulisher
Oct 07, 2025

BioCryst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo

Oct 07, 2025
pulisher
Oct 07, 2025

Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround - Yahoo Finance

Oct 07, 2025
pulisher
Oct 06, 2025

Custom strategy builders for tracking BioCryst Pharmaceuticals Inc.Weekly Trade Summary & Technical Pattern Based Signals - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

BioCryst Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Applying chart zones and confluence areas to BioCryst Pharmaceuticals Inc.July 2025 Short Interest & Technical Entry and Exit Tips - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

BioCryst Pharmaceuticals (BCRX): Exploring Valuation After Recent Share Price Drift - Sahm

Oct 05, 2025
pulisher
Oct 05, 2025

Will earnings trigger a reversal in BioCryst Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market - Insider Monkey

Oct 04, 2025
pulisher
Oct 04, 2025

JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛

Oct 04, 2025
pulisher
Oct 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

How to monitor BioCryst Pharmaceuticals Inc. with trend dashboardsQuarterly Profit Review & Low Risk Entry Point Guides - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

BioCryst (BCRX) Grants Stock Options and RSUs to New Employees - GuruFocus

Oct 03, 2025
pulisher
Oct 03, 2025

Is BioCryst Pharmaceuticals Inc. showing signs of accumulationQuarterly Market Summary & Verified Momentum Watchlists - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

115,000 Options & 91,450 RSUs — BioCryst Grants Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan

Oct 03, 2025
pulisher
Oct 02, 2025

BioCryst Pharmaceuticals Enters Oversold Territory (BCRX) - Nasdaq

Oct 02, 2025
pulisher
Oct 02, 2025

Biocryst sells European rights to HAE therapy Orladeyo for $250M - Angioedema News

Oct 02, 2025
pulisher
Oct 02, 2025

BioCryst Sells European ORLADEYO Business for $250M - The Globe and Mail

Oct 02, 2025
pulisher
Oct 02, 2025

10 Best Stocks to Buy Under $20 - Insider Monkey

Oct 02, 2025
pulisher
Oct 01, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.2%Here's Why - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Neopharmed Gentili completes acquisition of the European ORLADEYO® business from BioCryst Pharmaceuticals - firstonline.info

Oct 01, 2025
pulisher
Oct 01, 2025

Top chart patterns to watch in BioCryst Pharmaceuticals Inc.Market Risk Report & Reliable Intraday Trade Alerts - newser.com

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "In-Line" Rating at Evercore ISI - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst (BCRX) Finalizes European ORLADEYO Business Sale - GuruFocus

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst Pharmaceuticals Closes $250 Million Sale of Orladeyo Business in Europe - MarketScreener

Oct 01, 2025
pulisher
Oct 01, 2025

Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12 - MarketScreener

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst completes $250 million sale of European ORLADEYO business By Investing.com - Investing.com Nigeria

Oct 01, 2025
pulisher
Oct 01, 2025

H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst completes $250 million sale of European ORLADEYO business - Investing.com

Oct 01, 2025
pulisher
Oct 01, 2025

Biocryst completes sale of European Orladeyo (berotralstat) business - MarketScreener

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili - Quiver Quantitative

Oct 01, 2025
pulisher
Oct 01, 2025

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus - Stock Titan

Oct 01, 2025
pulisher
Sep 30, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Sep 30, 2025

Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Biocryst Pharmaceuticals Inc Azioni (BCRX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
HEGGIE THERESA
Director
Aug 13 '25
Sale
8.51
70,000
595,868
65,352
$19.76
price down icon 1.54%
$9.74
price down icon 2.50%
$53.95
price down icon 7.38%
drug_manufacturers_specialty_generic RDY
$14.34
price up icon 1.20%
$136.63
price down icon 1.33%
$440.00
price down icon 1.21%
Capitalizzazione:     |  Volume (24 ore):